

# Brief Table of Contents

*Preface*

*Acknowledgments*

*Additional Resources*

*Section Editors*

*Contributors*

*Detailed Table of Contents*

## VOLUME ONE

### SECTION 1: GENERAL PRINCIPLES

---

**Section Editors:** Mary G. Amato and Maria Kostka-Rokosz

- 1** Medication Therapy Management and Assessment of Therapy  
Matthew R. Machado, Joseph W. Ferullo, and Ameer Mistry
- 2** Interpretation of Clinical Laboratory Tests  
Erika Felix-Getzik, Yulia A. Murray, and Stefanie C. Nigro
- 3** Drug Interactions  
Michelle Ceresia, Caroline S. Zeind, John Fanikos, and Michael G. Carvalho
- 4** Pharmacogenomics and Personalized Medicine  
Hyun Kim, Shannon F. Manzi, Laura Chadwick, and Jonathan Picker
- 5** Managing Drug Overdoses and Poisonings  
Iris Sheinhait
- 6** End-of-Life Care  
Victoria F. Ferraresi and Mary Mihalyo
- 7** Interprofessional Practice and Education  
Michael G. Carvalho, Edith Claros, Christopher K. Cooper, and Kaelen C. Dunican

### SECTION 2: CARDIAC AND VASCULAR DISORDERS

---

**Section Editors:** Judy W. Cheng and Snehal H. Bhatt

- 8** Dyslipidemias, Atherosclerosis, and Coronary Heart Disease  
Barbara S. Wiggins and Pamela Morris
- 9** Essential Hypertension

Judy W. Cheng

**10** Peripheral Vascular Disorders

Snehal H. Bhatt

**11** Thrombosis

Nancy L. Shapiro and Erika L. Hellenbart

**12** Chronic Stable Angina

Angela M. Thompson and Toby C. Trujillo

**13** Acute Coronary Syndrome

Brianne Dunn and Robert Lee Page II

**14** Heart Failure

Harleen Singh and Joel C. Marrs

**15** Cardiac Arrhythmias

C. Michael White and James S. Kalus

**16** Hypertensive Crises

Sandeep Devabhakthuni, Ryan G. D'Angelo, and Michael Armahizer

**17** Shock

Jason S. Haney and Carolyn M. Bell

**SECTION 3: PULMONARY DISORDERS**

---

**Section Editors:** Timothy R. Hudd and Kathy Zaiken

**18** Asthma

Cary R. Chrisman and Christopher K. Finch

**19** Chronic Obstructive Pulmonary Disease

Timothy R. Hudd and Kathy Zaiken

**20** Acute and Chronic Rhinitis

Suzanne Bollmeier and Dennis M. Williams

**21** Cystic Fibrosis

Paul M. Beringer and Michelle Condren

**SECTION 4: GASTROINTESTINAL DISORDERS**

---

**Section Editor:** Carrie A. Sincak

**22** Nausea and Vomiting

Lisa M. DiGrazia and J. Todd Carter

**23** Upper Gastrointestinal Disorders

Elaine J. Law and Ricky B. Thumar

- 24** Lower Gastrointestinal Disorders  
Charmaine Rochester-Eyeguokan, Divita Singh, and Abigail Klutts
- 25** Complications of End-Stage Liver Disease  
Yasar O. Tasnif and Mary F. Hebert

## **SECTION 5: RENAL DISORDERS**

---

**Section Editors:** Susan A. Krikorian and Oussayma Moukhachen

- 26** Acid–Base Disturbances  
Mary P. Kovacevic, Jeremy R. DeGrado, and Kevin E. Anger
- 27** Fluid and Electrolyte Disorders  
Priscilla P. How and Alan H. Lau
- 28** Chronic Kidney Disease  
Adinoyi Garba
- 29** Acute Kidney Injury  
Susan A. Krikorian, Oussayma Moukhachen, and Alexander H. Flannery
- 30** Dialysis Treatment for Chronic Kidney Failure  
Michelle M. Richardson
- 31** Dosing of Drugs in Kidney Failure  
David J. Quan

## **SECTION 6: IMMUNOLOGIC DISORDERS**

---

**Section Editor:** Steven Gabardi

- 32** Drug Hypersensitivity Reactions  
Mariana C. Castells, Kathleen Marquis, and Kylie Marie Pesz
- 33** Systemic Lupus Erythematosus  
Jerika T. Lam, Ann M. Lynch, and Mary A. Gutierrez
- 34** Kidney and Liver Transplantation  
David J. Taber, Robert E. Dupuis, Nicole A. Pilch, and Kristen Szempruch

## **SECTION 7: NUTRITION ISSUES**

---

**Section Editors:** R. Rebecca Couris and Susan L. Mayhew

- 35** Basics of Nutrition and Patient Assessment  
Margaret K. Murphy, Leigh Furman, and Kathleen M. Gura
- 36** Obesity  
Kaelen C. Dunican and Aimee Dawson
- 37** Adult Enteral Nutrition

Carol J. Rollins

**38** Adult Parenteral Nutrition

Susan L. Mayhew and Richard S. Nicholas

## **SECTION 8: DERMATOLOGIC DISORDERS**

---

**Section Editor:** Katie Kiser

**39** Dermatotherapy and Drug-Induced Skin Disorders

Daniel R. Malcom and Lynn Z. Fuller

**40** Acne

Jamie J. Cavanaugh and Kelly A. Mullican

**41** Psoriasis

Rachel C. Long and Kelly A. Mullican

**42** Photosensitivity, Photoaging, and Burn Injuries

Molly E. Howard

## **SECTION 9: RHEUMATIC AND MUSCULOSKELETAL DISEASES**

---

**Section Editor:** Kamala M. Nola

**43** Osteoarthritis

Dominick P. Trombetta and Christopher M. Herndon

**44** Rheumatoid Arthritis

Janet S. Cho and Ying Wang

**45** Gout and Hyperuricemia

Troy Lynn Lewis and Kimmy Nguyen

**46** Connective Tissue Disorders

Steven S. Kheloussi, Julie L. Olenak, and Jonathan D. Ference

## **SECTION 10: WOMEN'S HEALTH**

---

**Section Editor:** Trisha LaPointe

**47** Contraception

Shareen El-Ibiary

**48** Infertility

Erin C. Raney

**49** Obstetric Drug Therapy

Trisha LaPointe

**50** Disorders Related to the Menstrual Cycle

Laura M. Borgelt and Karen M. Gunning

- 51** The Transition Through Menopause  
Louise Parent-Stevens and Trisha LaPointe

## **SECTION 11: ENDOCRINE DISORDERS**

---

**Section Editors:** Jennifer D. Goldman and David Schnee

- 52** Thyroid Disorders  
Eric F. Schneider and Kamaria K. Brown
- 53** Diabetes Mellitus  
Jennifer D. Goldman, Nikhil A. Sangave, and David Schnee

## **VOLUME TWO**

## **SECTION 12: EYE DISORDERS**

---

**Section Editor:** Susan Jacobson

- 54** Eye Disorders  
Katherine Carey and Bridget C. Hendricks

## **SECTION 13: NEUROLOGIC DISORDERS**

---

**Section Editors:** Michele Matthews and Adrian Wong

- 55** Pain and Its Management  
Virginia Ghafoor, Lee A. Kral, and Timothy J. Atkinson
- 56** Care of the Critically Ill Adult  
Philip Grgurich, Adrian Wong, and John Marshall
- 57** Multiple Sclerosis  
Melody Ryan
- 58** Headache  
Steven J. Crosby
- 59** Parkinson Disease and Other Movement Disorders  
Shedrick Martin and Kimberly Tallian
- 60** Seizure Disorders  
Sulaiman Almohaish, Melissa Sandler, Nicole E. Omecene, and Gretchen M. Brophy
- 61** Acute Ischemic and Hemorrhagic Stroke  
Oussayma Moukhachen and Philip Grgurich

## **SECTION 14: INFECTIOUS DISEASES**

---

**Section Editors:** Dorothea Rudolf, G. Christopher Wood, and Caroline S. Zeind

- 62** Principles of Infectious Diseases  
Joshua A. Garcia and B. Joseph Guglielmo
- 63** Antimicrobial Prophylaxis for Surgical Procedures  
Daniel J. G. Thirion
- 64** Vaccinations  
Molly G. Minze and Katie D. Ellis
- 65** Central Nervous System Infections  
Deanna J. Buehrle and Gregory A. Eschenauer
- 66** Endocarditis  
Annie Wong-Beringer, Rachid Douglas-Louis, and Emi Minejima
- 67** Respiratory Tract Infections  
Jason Cross, Evan Horton, and Dinesh Yogaratnam
- 68** Tuberculosis  
Michael B. Kays
- 69** Infectious Diarrhea  
Rupali Jain and David T. Bearden
- 70** Intra-Abdominal Infections  
Christie M. Bertram and Sheila K. Wang
- 71** Urinary Tract Infections  
Douglas N. Fish
- 72** Sexually Transmitted Diseases  
Albert Bach, Anne Walsh, and Karl M. Hess
- 73** Osteomyelitis and Septic Arthritis  
Jacqueline L. Olin, Linda M. Spooner, and Karyn M. Sullivan
- 74** Skin and Soft Tissue Infections  
Cheryl R. Durand and Kristine C. Willett
- 75** Prevention and Treatment of Infections in Neutropenic Cancer Patients  
Richard H. Drew and Steven W. Johnson
- 76** Pharmacotherapy of Human Immunodeficiency Virus Infection  
Aaron S. Devanathan, Allison E. Symonds, Jessica L. Adams, and Mackenzie L. Cottrell
- 77** Opportunistic Infections in Patients Living With HIV  
Emily L. Heil and Amanda H. Corbett
- 78** Fungal Infections  
John Cleary and Russell E. Lewis
- 79** Viral Infections

Sandra Benavides, Neeta Bahal O'Mara, and Milap C. Nahata

**80** Viral Hepatitis

Jerika T. Lam and Amy Kang

**81** Parasitic Infections

Sheila M. Seed, Janelle I. Herren, Samar E. Nicolas, Larry Goodyer, and Caroline S. Zeind

**82** Tick-Borne Diseases

Caroline S. Zeind, Michelle Ceresia, and Lin H. Chen

## **SECTION 15: PSYCHIATRIC DISORDERS AND SUBSTANCE ABUSE**

---

**Section Editors:** Michael C. Angelini and Michael G. Carvalho

**83** Anxiety Disorders

Tamara Bystrak and Amanda Eloma

**84** Sleep Disorders

Devon A. Sherwood and Anna K. Morin

**85** Schizophrenia

Richard J. Silvia, Robert L. Dufresne, and Justin C. Ellison

**86** Depressive Disorders

Michael C. Angelini

**87** Bipolar Disorders

Megan J. Ehret and Charles F. Caley

**88** Developmental Disorders

Kimberly Lenz and Neha Kashalikar

**89** Attention-Deficit Hyperactivity Disorder in Children, Adolescents, and Adults

Michael C. Angelini and Joel Goldstein

**90** Substance Use Disorders

Swati Betharia and Michael C. Angelini

**91** Tobacco Use and Dependence

Andrea S. Franks and Sarah E. McBane

## **SECTION 16: HEMATOLOGY AND ONCOLOGY**

---

**Section Editor:** Christy S. Harris

**92** Anemias

Cindy L. O'Bryant, Kate Deen Taucher, and Lisa A. Thompson

**93** Neoplastic Disorders and Their Treatment: General Principles

Michael Frei, Donyika Joseph, Kaiwen Wang, and Chelsea Wong

- 94** Adverse Effects of Chemotherapy, Immunotherapy, and Targeted Agents  
Victoria Nachar and Matthew Newman
- 95** Pediatric Malignancies  
M. Brooke Bernhardt and Nicole A. Kaiser
- 96** Adult Hematologic Malignancies  
Casey B. Williams, Rachel Elsey, Sarah M. Hayes, and Jacob K. Kettle
- 97** Breast Cancer  
Kellie Jones Weddle
- 98** Lung Cancer  
Maryann R. Cooper
- 99** Colorectal Cancer  
Marlo Blazer and Joshua Reardon
- 100** Prostate Cancer  
Marina D. Kaymakcalan and Christy S. Harris
- 101** Hematopoietic Stem Cell Transplantation  
Valerie Relias

## **SECTION 17: PEDIATRICS**

---

**Section Editor:** Elizabeth Anne Farrington

- 102** Pediatric Pharmacotherapy  
Elizabeth Anne Farrington
- 103** Pediatric Fluid, Electrolytes, and Nutrition  
Jennifer W. Chow and Lisa M. Feagin
- 104** Common Pediatric Illnesses  
Chephra McKee and Gildon Brooke
- 105** Neonatal Therapy  
Jennifer T. Pham and Kirsten H. Ohler
- 106** Care of the Critically Ill Child  
Elizabeth Anne Farrington

## **SECTION 18: GERIATRIC THERAPY**

---

**Section Editor:** Judith L. Beizer

- 107** Geriatric Drug Use  
Suzanne Dinsmore, Mary-Kathleen Grams, and Kristin M. Zimmerman
- 108** Geriatric Neurocognitive Disorders  
Nicole J. Brandt and Stephanie M. Ozalas



**109** Geriatric Urologic Disorders

Jaini Patel

**110** Osteoporosis

Mary-Kathleen Grams, R. Rebecca Couris, and Suzanne Dinsmore

*Drug Index*

*Subject Index*

*[www.abadisteb.pub](http://www.abadisteb.pub)*

Aclidinium bromide (Tudorza PressAir), umeclidinium bromide (Incruse Ellipta), and glycopyrrolate (Seebri Neohaler) are other long-acting anticholinergics approved for the long-term maintenance treatment of COPD. These agents have been shown to improve lung function and are well tolerated.<sup>113–115</sup>

J.O. should be started on a long-acting bronchodilator, such as salmeterol or tiotropium. Once-daily  $\beta$ -agonists such as indacaterol or olodaterol are additional options to consider. Recently approved anticholinergics such as aclidinium bromide, glycopyrrolate, or umeclidinium bromide are other potential options. It should be noted that the tolerability and efficacy of the available long-acting bronchodilators are comparable. The choice of agent is largely based on considerations such as the frequency of drug administration, the patient's ability to use the inhalation device correctly, and any out-of-pocket costs incurred by the patient. J.O. should also be instructed to continue her albuterol two puffs every 4 hours as needed for breakthrough symptoms. A follow-up visit should be scheduled to assess her response.

**CASE 19-2, QUESTION 2:** J.O. is started on tiotropium respimat, inhale 5  $\mu$ g daily and returns to the office for a follow-up visit 3 months later. She has had significant benefit from the medication and has had decreased wheezing and a noticeable improvement in her exercise tolerance. She asks to have spirometry repeated to see whether her lung function has improved on the new medication. Spirometry is repeated, and no significant improvement is noted in her FEV<sub>1</sub>. How can she feel better, with improved exercise tolerance, without an improvement in her lung function?

Increasing evidence suggests that bronchodilators, including LABAs and anticholinergics, may reduce exercise-related dyspnea in patients with COPD by decreasing dynamic hyperinflation.<sup>116</sup> This improvement may be independent of marked changes in spirometry performed at rest. Indeed, because of flow limitation, these patients who exercise can have significant worsening of air trapping, which can worsen lung compliance and adversely affect respiratory muscle mechanics. A number of studies have shown that alleviation of such dynamic hyperinflation may be an important mechanism whereby bronchodilators improve exercise tolerance in patients with obstructive lung disease.<sup>116</sup>

**CASE 19-2, QUESTION 3:** J.O. seemed to do reasonably well for a number of years, but now, 3 years later, she has noticed progressive dyspnea on exertion. She is now having difficulty carrying laundry up from her basement, and she has noticed that her overall activity level has been curtailed. Repeat office spirometry now shows an FEV<sub>1</sub>/FVC ratio of 0.49 and an absolute FEV<sub>1</sub> of 40% of predicted. She now has a CAT score of 22 and has had two exacerbations in the past year. J.O. has been adherent with her tiotropium regimen and has had no other significant changes to her medical history. She remains smoke free and is not exposed to secondhand smoke in her home and work environments. What therapeutic intervention(s) should be considered at this point?

### INHALED CORTICOSTEROID THERAPY

J.O. has had significant deterioration in status and repeated COPD exacerbations despite appropriate adherence to tiotropium. Before modifying therapy, proper inhaler technique, medication adherence, and impact of nonpharmacologic interventions should be assessed. Combination therapy with either LAMA + LABA or ICS + LABA should be considered in patients with persistent symptoms or who continue to experience exacerbations despite appropriate use and adherence to long-acting bronchodilator monotherapy.<sup>1</sup> Fixed-dose combination products are preferred, and several options are commercially available (Table 19-3). LAMA + LABA therapy may be preferred, given the absence of asthma or atopic conditions and without elevated serum eosinophil levels and other biomarkers associated with ICS response. Also, dual bronchodilator therapy has a lower incidence of pneumonia, when compared to regimens containing an ICS. An LAMA + LABA combination was superior to an ICS + LABA in preventing exacerbations and other patient-reported outcomes in those with a history of prior exacerbations.<sup>117</sup> Several corticosteroid LABA inhalers are available and indicated for COPD, including Advair (fluticasone–salmeterol), Symbicort (budesonide–formoterol), and Breo Ellipta (fluticasone–vilanterol). No convincing data suggest that one preparation is superior to the other in the treatment of COPD. However, a number of multicenter, randomized, controlled clinical trials have demonstrated the efficacy of ICS in COPD.<sup>78,83</sup> The data have supported the use of ICS in advanced COPD and in patients with frequent exacerbations. ICS responsiveness may be further predicted by the presence of elevated eosinophils ( $\geq 300$  cells/ $\mu$ L) or underlying asthma.<sup>1</sup> Moreover, regular use of ICS can decrease the frequency of acute exacerbations and improve health-related quality of life in patients with an FEV<sub>1</sub> <60% of predicted.<sup>22</sup>

**Table 19-3**  
**Inhaled Therapeutic Options for COPD**

Medication Brand Name and Strength (per Inhalation)	Chemical Name	Device	No. of Doses <sup>a</sup> /Device or Box
<b>Short-Acting <math>\beta_2</math> Agonists</b>			
<sup>c</sup> ProAir HFA 90 $\mu$ g, <sup>c</sup> Proventil HFA 90 $\mu$ g, <sup>c</sup> Ventolin HFA 90 $\mu$ g	Albuterol	MDI	200 <sup>b</sup>
ProAir, RespiClick 90 $\mu$ g	Albuterol	DPI	200
<sup>c</sup> AccuNeb 0.63 mg/3 mL, 1.25 mg/3 mL	Albuterol	Nebulizer	Varies
ProAir <sup>®</sup> Digihaler™	Albuterol	DPI	200
<sup>c</sup> Proventil 2.5 mg/3 mL (0.083%), <sup>e</sup> 5 mg/mL (0.5%) concentrate	Albuterol	Nebulizer	Varies
<sup>c</sup> Xopenex HFA 45 $\mu$ g	Levalbuterol	MDI	200 <sup>b</sup>
<sup>c</sup> Xopenex 0.31 mg/3 mL, 0.63 mg/3 mL, 1.25 mg/3 mL, <sup>e</sup> 1.25 mg/0.5 mL concentrate	Levalbuterol	Nebulizer	Varies
<b>Short-Acting Anticholinergic</b>			
Atrovent HFA 17 $\mu$ g	Ipratropium	MDI	200 <sup>b</sup>
<sup>c</sup> Atrovent 0.02% (0.5 mg/2.5 mL) vial	Ipratropium	Nebulizer	25ct, 30ct, 60ct
<b>Short-Acting Anticholinergic + <math>\beta_2</math>-Agonist Combination</b>			
Combivent Respimat 20–100 $\mu$ g	Ipratropium + Albuterol	SMI	120 <sup>b</sup>
<sup>c</sup> DuoNeb 0.5–2.5 mg/3 mL vial	Ipratropium + Albuterol	Nebulizer	30ct, 60ct
<b>Long-Acting <math>\beta_2</math>-Agonists</b>			
Serevent Diskus 50 $\mu$ g	Salmeterol	DPI	60
Brovana 15 $\mu$ g/2 mL vial	Arformoterol	Nebulizer	30ct, 60ct
Perforomist 20 $\mu$ g/2 mL vial	Formoterol	Nebulizer	30ct, 60ct
Arcapta Neohaler 75 $\mu$ g	Indacaterol maleate	DPI	30 blister units
Striverdi Respimat 2.5 $\mu$ g	Olodaterol	SMI	60 <sup>b</sup> (30 doses)
<b>Long-Acting Anticholinergics</b>			
Spiriva HandiHaler 18 $\mu$ g	Tiotropium	DPI	30 blister units
<sup>d</sup> Spiriva Respimat 2.5 $\mu$ g	Tiotropium	SMI	60 <sup>b</sup> (30 doses)
Tudorza Pressair 400 $\mu$ g	Aclidinium bromide	DPI	60
Incruse Ellipta 62.5 $\mu$ g	Umeclidinium	DPI	30
Seebri Neohaler 15.6 $\mu$ g	Glycopyrrolate	DPI	60 blister units
Lonhala Magnair 25 $\mu$ g/mL	Glycopyrrolate	Nebulizer	60ct
Yupelri 175 $\mu$ g/3 mL	Reprofenacin	Nebulizer	30ct
<b>Long-Acting Anticholinergic + <math>\beta_2</math>-Agonist Combination</b>			
Anoro Ellipta 62.5–25 $\mu$ g	Umeclidinium + Vilanterol	DPI	60
Stiolto Respimat 2.5–2.5 $\mu$ g	Tiotropium + Olodaterol	SMI	60 <sup>b</sup> (30 doses)
Utibron Neohaler 15.6–27.5 $\mu$ g	Glycopyrrolate + Indacaterol	DPI	60 blister units
Bevespi Aerosphere 9–4.8 $\mu$ g	Glycopyrrolate + Formoterol	MDI	120 <sup>b</sup>
Duaklir Pressair 400–12 $\mu$ g	Aclidinium + Formoterol	DPI	60
<b>Inhaled Corticosteroid + Long-Acting <math>\beta_2</math>-Agonist Combination</b>			
<sup>c,d</sup> Advair Diskus 250–50 $\mu$ g	Fluticasone + Salmeterol	DPI	60
<sup>c,d</sup> Symbicort HFA 160–4.5 $\mu$ g	Budesonide + Formoterol	MDI	120 <sup>b</sup>
<sup>d</sup> Breo Ellipta 100–25 $\mu$ g	Fluticasone + Vilanterol	DPI	60
<b>Inhaled Corticosteroid + Long-Acting Anticholinergic + <math>\beta_2</math>-Agonist Combination</b>			
<sup>b,d</sup> Trelegy Ellipta 100-62.5-25 $\mu$ g	Fluticasone furoate + umeclidinium + vilanterol	DPI	60
Breztri Aerosphere 160-9-4.8 $\mu$ g	Budesonide + glycopyrrolate + formoterol	MDI	120 <sup>b</sup>

DPI, dry-powder inhaler; MDI, metered-dose inhaler; SMI, soft mist inhaler.

<sup>a</sup>Generic formulations available.

<sup>b</sup>Only FDA-approved strength for COPD other strengths may be commercially available.

<sup>c</sup>Institutional sizes not included.

<sup>d</sup>Number of doses after initial priming.

<sup>e</sup>Nebulized solutions marked “0.5- mL concentrate” should be diluted with 0.9% sodium chloride solution.

The TORCH study has defined the benefits and potential side effects of ICS in a broader patient population of COPD.<sup>57</sup> In this multicenter, randomized, placebo-controlled study, mean FEV<sub>1</sub> was 50% of predicted, but entry criteria did not require a history of repeated exacerbations. More than 6000 patients were randomly assigned to either an ICS (fluticasone 500  $\mu$ g bid), inhaled salmeterol (50  $\mu$ g bid), combined fluticasone 500  $\mu$ g and salmeterol 50  $\mu$ g bid, or placebo. Subjects were assessed for ~3 years. A significant benefit was seen as measured by decreased exacerbation rates in subjects taking either inhaled fluticasone or a combination of fluticasone–

salmeterol therapy. Also, an improvement was found in mortality with combination therapy that approached, but did not reach statistical significance. Overall adverse side effects with ICS were similar to those with placebo. An increased risk, however, was seen for lower respiratory tract infections with inhaled fluticasone or fluticasone-salmeterol. Of note, patients did not experience an increased risk of ocular manifestations or decreased boFFigurene density with ICS treatment.

J.O. is already taking tiotropium, so a decision must be made regarding step-up therapy. Proper inhalation technique and adherence should be confirmed before escalating therapy. LAMA + LABA is the preferred regimen for this patient, given her persistent symptom burden and high frequency of exacerbations over the past year despite LAMA monotherapy. Tiotropium + olodaterol is one possible fixed-dose combination product that may replace tiotropium. J.O. is already familiar with the Respimat device, which may help maintain adherence. If J.O. is experiencing difficulty with using the respimat, several alternative long-acting dual bronchodilator products are available in different inhaled delivery devices.

**CASE 19-2, QUESTION 4:** J.O. calls the next day, having read something on the Internet regarding possible increased risk of death in people with obstructive lung disease who take long-acting bronchodilators. She is reluctant to take it. What should you tell her?

### SAFETY OF LONG-ACTING BRONCHODILATORS

Although some evidence in asthma indicates that the use of long-acting bronchodilators may be associated with an increased risk of death, such evidence does not exist in patients with COPD. In fact, the TORCH study demonstrated no increased risk of death or adverse events among patients prescribed salmeterol compared with placebo.<sup>57</sup> Other trials designed to evaluate the safety of bronchodilator use have resulted in similar findings.<sup>61,62,102,111</sup> The patient should be reassured that long-acting bronchodilators are safe in COPD.

### PULMONARY REHABILITATION

**CASE 19-2, QUESTION 5:** J.O. also wonders whether anything else other than her medication can be done for her. What advice might be given?

At this point, pulmonary rehabilitation should be strongly considered. In fact, a comprehensive multidisciplinary pulmonary rehabilitation program should be considered in any patient with COPD experiencing persistent shortness of breath despite pharmacologic management.<sup>1,46</sup>

Increasing evidence points to COPD as a systemic process,<sup>118</sup> and pulmonary rehabilitation addresses the systemic nature of the disease. Although the proximate cause of disability involves the respiratory system, leading to dyspnea on exertion, this, in turn, has systemic consequences. Although the changes may be fairly subtle to start with, most patients will gradually manifest increasing limitations in their activity. This results in substantial deconditioning. It is likely that this deconditioning, in addition to other factors such as systemic inflammation, adversely affect skeletal muscle function. Indeed, evidence is clear that oxidative capacity is diminished in patients with COPD,<sup>47-49</sup> which results in overall decreased aerobic capacity and increased lactic acid production for a given level of activity.<sup>50</sup> The increased acid load will lead to a greater requirement for ventilation, which makes dyspnea more severe. The more dyspneic the patient is, the less activity he or she will do, leading to more deconditioning and recapitulation of the downward spiral.

Pulmonary rehabilitation is an exercise-based, multidisciplinary program that seeks to address this cycle.<sup>1</sup> Most programs generally last 8 to 12 weeks and involve two to three sessions per week.<sup>46</sup> Education, particularly about medication use, as well as psychosocial counseling and breathing retraining are important components of the program. An important component of breathing retraining involves coaching patients how to use pursed-lip breathing effectively. Pursed-lip breathing involves pursing the lips together (as in whistling) during exhalation. This helps to slow down respirations and also provides a back pressure in the small airways, preventing dynamic airway collapse and exercise-induced hyperinflation. The major intervention, however, is exercise training, especially endurance training of the lower extremities (eg, using a treadmill or bicycle ergometer). Numerous studies have demonstrated that a rehabilitation program can significantly improve exercise capacity and quality of life, as well as decrease health care utilization.<sup>51</sup> This may partly be related to the beneficial effects of exercise on the oxidative capacity of the skeletal muscles.

J.O. should be referred to a local outpatient pulmonary rehabilitation program. A typical program involves 2-hour sessions, two to three times per week for 8 to 12 weeks. The sessions will involve education, breathing retraining, and strength and endurance exercise training.

basophils, eosinophils, neutrophils, macrophages, and leukotrienes, play important roles.<sup>4</sup> These additional mediators, attracted to the area through chemotaxis, sustain the inflammatory response.<sup>4</sup> Also, some chemotactic proteins can cause damage to the airway epithelium and expose local nerve fibers.<sup>4</sup> Continued exposure to the offending allergen can also prolong the late-phase reaction.

## CLINICAL PRESENTATION AND ASSESSMENT OF RHINITIS

The diagnosis of rhinitis is not defined by one specific laboratory test; rather, it is related to the coordinated results of a thorough patient interview, including medication history, pertinent physical examination, and a limited number of relevant laboratory assessments.

### Risk Factors

Several elements increase the risk of developing allergic rhinitis. Atopy, parental history, introduction of formula in infancy, exposure to maternal smoking at age younger than 1 year, serum IgE levels >100 IU/mL before age 6 years, ethnic origin other than White European, environmental pollution, birth during pollen season, no older siblings, late entry into nursery or preschool, and exposure to indoor allergens such as animal dander and dust mites as well as concomitant food allergies<sup>26</sup> are risk factors.<sup>5</sup>

### History, Signs, and Symptoms

A history should be obtained from the patient that includes details of the onset (including seasonality),<sup>3</sup> character, frequency, duration, and severity of the patient's symptoms and any identifiable factors that provoke or relieve these symptoms.<sup>5</sup> Past medical history (including the age of onset of symptoms) and family history (eg, atopy) are also helpful.<sup>5</sup> Other symptoms such as sleep problems, snoring, repeated sniffing, and allergic salute and shiner should also be noted.<sup>3</sup>

Both allergic and nonallergic forms of rhinitis are common and can potentially coexist.<sup>2</sup> Diagnostic criteria suggestive of allergic rhinitis include nasal discharge, itching, sneezing, and nasal congestion.<sup>3</sup> Occasionally, patients will present with a decreased sense of smell.<sup>5</sup> Symptoms of allergic conjunctivitis include itchy, watery eyes,<sup>5</sup> which occur in ~50% to 70% of patients with allergic rhinitis. Their presence can be used to differentiate allergic rhinitis from other forms.<sup>5</sup> Persistent congestion and/or rhinorrhea<sup>25</sup> like changes in temperature, air conditioning, pollutants, tobacco smoke, and other irritants suggest that nonallergic triggers may be involved. The negative impact of rhinitis on a patient's quality of life can be substantial, and it is important to assess this during the patient interview. Symptoms and symptom-induced interference with necessary (ie, work, school) and enjoyable (eg, hobbies, family events) activities can lead to patient anger, sadness, irritation, and withdrawal.<sup>5</sup> The questions listed in **Figure 20-4** provide a guide to collecting the information needed to initiate and modify therapy based on the underlying causes of the rhinitis symptoms.

1. Which of the common symptoms of rhinitis is the patient experiencing?
  - Sneezing, nasal itching, runny nose, nasal congestion, postnasal drip, altered sense of smell, watery eyes, itching eyes, ear “popping”
2. What color are the nasal secretions?
  - Clear, white, yellow, green, blood-streaked, rusty brown
3. When did the symptoms first appear?
  - Infancy, childhood, adulthood
4. Were the symptoms associated with a change in state/environment?
  - After a viral upper respiratory infection, after a traumatic blow to the head or face, upon moving into/visiting a new dwelling, after obtaining a new pet
5. How often do the symptoms occur?
  - Daily, episodically, seasonally, constantly
6. For how long has this symptom pattern persisted?
  - Days, weeks, months, years
7. Which factors or conditions precipitate symptoms?
  - Specific allergens, inhaled irritants, climatic conditions, food, drinks
8. Which specific activities precipitate symptoms?
  - Dusting, vacuuming, mowing grass, raking leaves
9. Are other members of the family experiencing similar symptoms?
10. Which of the following are prevalent in the household?
  - Carpeting, heavy drapes, foam or feather pillows, stuffed toys, areas of high moisture (basements, bathrooms), tobacco use (by patient or others), pets
11. Does the patient have other medical conditions that can cause similar symptoms?
12. Is the patient taking any medications that might cause or aggravate these symptoms?
13. What prescription and nonprescription medications have been used for these symptoms in the past? Were they effective? Did they cause any unwanted effects?
14. What is the patient's occupation?
15. What are the patient's typical leisure activities?
16. To what extent have the symptoms interfered with the patient's lifestyle (ie, are they disabling or merely annoying)?
  - Greatly, somewhat, not much

**Figure 20-4** Patient history interview.

## Diagnosis

### PHYSICAL EXAMINATION

During a physical examination for rhinitis, the patient's nose should be inspected for the position of the septum, appearance of the nasal mucosa, secretions, and any growths.<sup>3</sup> Common physical characteristics of patients with allergic rhinitis are clear nasal discharge, swollen nasal membranes,<sup>4</sup> allergic shiners (discoloration under the